Temsirolimus is a water-soluble mammalian target of rapamycin (mTOR) complex inhibitor, potentially suitable for intra-articular administration. The present study aims to evaluate the therapeutic effects of intra-articular administration of temsirolimus on human chondrocytes and osteoarthritis (OA) progression in mice. The beneficial effects of temsirolimus treatment were evaluated in human chondrocytes (Normal Human Articular Chondrocyte-Knee cells) with or without treatment with IL-1β in vitro by real-time polymerase chain reaction, TUNEL staining for apoptosis, and CYTO-ID(R) staining for autophagy. The therapeutic effect of intra-articular injection of temsirolimus was evaluated in OA models (destabilized medial meniscus in C57BL/6J and senescence accelerated mice prone 8 (SAMP8)) in vivo, by histological and immunohistochemical analyses. Temsirolimus treatment upregulated COL2A1 and aggrecan (a major proteoglycan in the articular cartilage) expression in human chondrocytes. In addition, temsirolimus treatment recovered IL-1β-induced down-reregulated COL2A1 and aggrecan expression, while it partially decreased upregulated MMP-1, MMP-13, ADAMTS-4, ADAMTS-5, IL-1β, and IL-6 expression and apoptosis in human chondrocytes. Further, temsirolimus treatment enhanced autophagic activity in human chondrocytes. The intra-articular injection of temsirolimus to 12-week and 1-year old wild-type surgically induced OA model mice and SAMP8 mice delayed OA progression as compared to that in the control mice. Temsirolimus treatment protected human chondrocytes from IL-1β-induced OA gene expression changes and apoptosis. Intra-articular injection of temsirolimus delayed OA progression in the mouse OA model and in SAMP8 mice. Thus, the intra-articular administration of temsirolimus is a promising therapeutic approach to inhibit articular cartilage degradation.
19 September 2026 in Journal of Orthopaedic Research
Background: Ramp lesions and lateral meniscal oblique radial tears (LMORTs) have been suggested to influence knee laxity; however, dynamic changes associated with these lesions remain incompletely understood. Purpose: To quantitatively evaluate changes in knee laxity associated with the sequential addition of a ramp lesion and LMORT in anterior cruciate ligament (ACL)–deficient knees using whole cadaveric lower limbs. Study Design: Controlled laboratory study. Methods: Ten fresh-frozen cadaveric lower limbs were tested under 4 sequential conditions: ACL intact (ACLI), ACL deficient (ACLD), ACLD with a ramp lesion, and ACLD with a ramp lesion and LMORT. Knee laxity was quantitatively assessed with an electromagnetic sensor system. Anterior tibial translation (ATT) was measured during the Lachman test and anterior drawer test at 30°, 60°, and 90° of flexion, as were anterior-posterior tibial translation and posterior tibial acceleration during the pivot-shift test. Comparisons among the 4 conditions were performed by repeated measures analysis of variance, followed by paired t tests with Holm adjustment for multiple comparisons. Results: During the anterior drawer test at 60° of flexion, ATT increased from 7.6 ± 3.7 mm (mean ± SD) in the ACLI group to 9.5 ± 3.3 mm in the ACLD group and 10.5 ± 2.9 mm in the ramp group. ATT was significantly greater in the ramp group than in the ACLI group (mean paired difference, 2.9 mm; 95% CI, 1.7-4.0; P = .002). However, no statistically significant difference was detected between the ACLI and ACLD groups ( P = .064) or between the ACLD and ramp groups ( P = .161). After the addition of LMORT, posterior tibial acceleration during the pivot-shift test increased from 2.0 ± 1.0 to 2.9 ± 0.9 m/s 2 . Conclusion: In this sequential whole-limb model, a concomitant ramp lesion may contribute to anterior laxity at midflexion, while the subsequent addition of LMORT was associated with a further increase in posterior tibial acceleration during the pivot-shift maneuver. Clinical Relevance: These findings highlight the importance of considering concomitant ramp lesions and LMORTs when evaluating knee laxity in ACL-deficient knees.